AMCP Develops 2020 Policy and Advocacy Focus Areas; CMS Issues CY 2021 Advanced Notice for MA Capitation Rates and Part C and Part D Payment Policies – Part II; CMS Issues CY 2021 and 2022 Medicare Advantage and Part D Proposed Rule; CMS Releases New Guidance on Medicaid Waiver Flexibility
AMCP CEO Blog: AMCP has been working hard for several years to help members be ready when drugs are approved or off-label indications emerge. The first prong of our effort was to update the popular AMCP Format for Formulary Submissions.
On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released Part II of the Advance Notice of Methodological Changes for Calendar Year (CY) 2021 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, outlining proposed payment changes and other requirements for plan sponsors participating in MA and the Part D program for the upcoming contract year.
On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released the CY 2021 and 2022 Medicare Advantage and Medicare Prescription Drug Benefit Program Policy and Technical Rule, outlining proposed programmatic changes to the MA and Part D programs for two upcoming contract years. In a break from historic precedent, many of the program and policy changes that historically had been included in the Draft Call Letter were included in this proposed rule.
AMCP Submits Comments to HHS OIG on Proposed Revisions to AKS Safe Harbors; AMCP to Comment on White House Proposal to Allow Drug Importation; FDA Issues Draft Guidance on Interchangeable Insulin; AMCP Invited to Participate in Pharmaceutical Quality Workshop
JMCP has added two prominent academic health care researchers to its editorial team, a move designed to keep pace with the growing influence of AMCP’s peer-reviewed, scientific journal.